Lecture Details - Table of Contents

10th International Lung Cancer Congress

Release Date: June 24, 2009| Jun 17-20, 2009, Kohala Coast, HI

Table of Contents

Early-Stage NSCLC

Neoadjuvant Chemotherapy
Joan H. Schiller

Adjuvant Therapy for NSCLC
Heather Wakelee

Debate: Stage vs. Molecular Markers in Stage IIA NSCLC
Markers
Giorgio Scagliotti

Debate: Stage vs. Molecular Markers in Stage IIA NSCLC
Stage
Kemp H. Kernstine

Debate: Radiation Therapy vs. Surgery in Early-Stage NSCLC
Radiation
Walter Curran, Jr

Debate: Radiation Therapy vs. Surgery in Early-Stage NSCLC
Surgery
David M. Jablons

When Are Sublobar Resections Appropriate?
Stephen Swisher

Panel Discussion: IASLC Staging
Project Harvey I. Pass, Paul Baas, David Gandara, Hak Choy

Keynote Lecture: BATTLE Program for Personalized Medicine
Roy Herbst

Angiogenesis Inhibition

Overview of Angiogenesis Inhibition
Roy Herbst

Combination Regimens to Inhibit Multiple Signaling Pathways
Glenwood Goss

Managing Toxicities of Antiangiogenic Agents: Practical Advice for the Clinic
Karen Kelly

Poster Discussion 1
H. Jack West

Workshop 1: The Next Generation of Targeted Agents in Lung Cancer (CME-Designated Workshop)

Overview
Paul A. Bunn, Jr

P13K/Akt Inhibitors
Roy Herbst

Apoptosis Inducers-Extrinsic
Karen Kelly

Apoptosis Inducers-Intrinsic
Primo N. Lara, Jr

FGF Inhibitors
Philip C. Mack

c-Met Inhibitors
Román Pérez-Soler

Hedgehog Inhibitors
David Gandara

Hsp90 Inhibitors
H. Jack West

EGFR Inhibitors in NSCLC

Population-Specific Implications of Anti-EGFR Agents
Paul A. Bunn, Jr

Overcoming Resistance to EFGR TKIs; Second-Generation TKIs
Heather Wakelee

Update on EGFR Antibodies in NSCLC
Román Pérez-Soler

Second Annual Addario Foundation Keynote Lecture: Mesothelioma
Harvey I. Pass

Multi-Targeted Agents

What’s New with Multikinase Inhibitors
Roy Herbst

Update on HDAC Inhibitors
Primo N. Lara, Jr

Personalized Medicine

Overview of Personalized Medicine
Paul A. Bunn, Jr

Biomarkers for Personalized Lung Cancer Therapy
Fred Hirsch

Role of Pathology/Molecular Diagnostics
Ignacio Wistuba

Supportive Care

Poster Discussion 2
Randeep Sangha, MD

Current and Future Management Strategies for Metastatic Bone Disease
Corey Langer

Workshop 2: Multidisciplinary Tumor Board (CME-Designated Workshop)

Surgery-Oriented Case
Harvey I. Pass

Early Stage with Poor Pulmonary Function
Water Curran, Jr

PCI for Stage III NSCLC
Water Curran, Jr

Optimizing Combined Modality Therapy for Lung Cancer

Chemoradiation Therapy for Stage III NSCLC: State-of-the-Art
A. William Blackstock

Introducing New Agents Into Combined Modality Therapy for NSCLC
Martin Edelman

Surgical Approaches in Locally Advanced NSCLC
Stephen Swisher

Innovative Approaches to Radiation Therapy, Including SBRT, IMRT, and Proton Beam Therapy
Hak Choy

Current Approaches to the Treatment of LD-SCLC
Walter Curran, Jr

Treatment of Advanced Lung Cancer

Lung Cancer Vaccines
David M. Jablons

Novel Cytotoxics in Metastatic NSCLC
Martin Edelman

Approaches to the Second-line Treatment of Metastatic NSCLC
Román Pérez-Soler

Optimal Application of Antifolates in NSCLC
David Gandara

Maintenance Therapy for NSCLC
Karen Kelly

Treatment of ED-SCLC
Primo N. Lara, Jr

IGF-1R Inhibitors
Randeep Sangha

Cooperative Group Update

Japan
Nagahiro Saijo

Europe
Paul Baas

SWOG
David Gandara

RTOG
Hak Choy

NCIC
Glenwood Goss

NCCTG
Alex Adjei

ECOG
Joan H. Schiller

CALGB
Martin Edelman

ACOSOG
Kemp H. Kernstine

Instructions for Participation

To view the streaming Flash Video lectures, click the "View Flash Presentation" link. The latest version of Flash Player is recommended to view the Flash video.
Click here to download Flash Player >>

To download Podcast-ready movies, click "Download Video Podcast," and select "Save target as..." The latest version of Quicktime is recommended to view these movies.
Click here to download Quicktime >>

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclaimer
Physicians’ Education Resource presents this resource for educational purposes only. Participants are expected to use their own expertise and judgment while engaged in the practice of medicine. Please consult full prescribing information for any drugs or procedures discussed within.

The views and opinions expressed in these presentations are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Disclosure of Unlabeled Uses
This reference may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference.

All rights reserved; for personal use only. No part of this presentation may be translated, reproduced or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Educational Grants

An educational grant for this activity was provided by:


  1. Bristol-Myers Squibb/ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
  2. Eli Lilly and Company
  4. AstraZeneca
  5. GlaxoSmithKline
  7. Millennium Pharmaceuticals
  8. sanofi-aventis U.S.
  9. The Bonnie J. Addario Lung Cancer Foundation